1. Melnikova I. Pain market. Nat Rev Drug Discov. 2010;9:589–90.
2. Dworkin R, Turk D, Katz N, Rowbotham M, Peirce-Sandner S, Cerny I, Clingman C, Eloff B, Farrar J, Kamp C, McDermott M, Rappaport B, Sanhai W. Evidence-based clinical trial design for chronic pain pharmacotherapy: a blueprint for ACTION. Pain. 2011;152:S107–15.
3. McQue K. Newron’s ralfinamide fails for Katie McQue neuropathic pain. SCRIP World Pharmaceutical News. 7 May 2010.
http://s3.amazonaws.com/cuttings/cuttingpdfs/9547/217fd9e47def65479dc4933329b5eb24.pdf
.
4. Schmidt W. 6th annual pain therapeutics summit. Oct 2013.
www.painresearchforum.org/news/22419-filling-pain-drug-pipeline
.
5. ClinicalTrials.gov Identifier: NCT01693692, Sponsor Theravance, first received Sept 20, 2012.
http://www.clinicaltrials.gov/ct2/show/NCT01693692
.